JCR’s GVHD 1.5 Years Ahead Of Schedule, Application Planned For 2014
This article was originally published in PharmAsia News
Executive Summary
JCR Pharmaceuticals announced Nov. 19 they reached the target number of cases for domestic Phase II/III trials for JR-031, a drug the company is developing for the treatment of graft-versus-host disease, a serious complication that occurs during hematopoietic stem cell and bone marrow transplantation.
JCR Pharmaceuticals announced Nov. 19 they reached the target number of cases for domestic Phase II/III trials for JR-031, a drug the company is developing for the treatment of graft-versus-host disease, a serious complication that occurs during hematopoietic stem cell and bone marrow transplantation. According to the company, the target of 25 cases was reached approximately 1.5 years ahead of schedule. The company therefore estimates that an application for domestic approval will be filed in 2014. JCR acquired rights for independent development of the drug from American firm Osiris. Phase I/II trials started in 2007 and Phase II/III trials began in August 2011. Click Here For More – Japanese Language
“JCR Reaches Case Target 1.5 Years In Advance For Phase II/III Trials, Plans Application For 2014” mixonline.jp 11/21/2012